Aurinia Pharmaceuticals (AUPH) Stock Price Slips After Q3 Earnings Strength

Aurinia Pharmaceuticals came into this Q3 2026 report with a reputation for eye catching profitability and a stock priced as if that might not last. The latest numbers show quarterly net income of US$31.7 million on revenue of US$83.7 million, yet the share price slipped 3.3% on the first full trading day after the release to US$16.65. That gap between rich reported earnings and a falling ticker is the story. Investors are weighing a very high trailing net margin against forecasts for only modest revenue growth ahead.

Love Aurinia Pharmaceuticals' eye catching net margin but concerned the share price is treating it as temporary? Take a look at our 30 high quality undervalued stocks.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$83.7 million vs. US$73.5 million (up about 14%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$31.7 million vs. US$31.6 million (broadly flat)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.24 vs. US$0.24 (steady year over year)
• Trailing Net Margin (Last 12 Months vs. Prior Year): 97.7% vs. 29.3% (very large improvement with unusually high profitability)

Aurinia’s net margin just leapt to an unusual 97.7%. Ask Charlie what makes Aurinia’s margin jump look sustainable.

Aurinia’s Bull Case Meets Concrete Milestones

Supporters argue Aurinia Pharmaceuticals is no longer just a single drug story but an emerging autoimmune platform that must grow without breaking its improved economics.

"The main thing that has to go right is that Aurinia successfully scales its broader autoimmune pipeline, including aritinercept and the acquired Kezar assets, without eroding the improved profitability and cash generation achieved in 2025."

Q3 results show that test is partly being met. The firm is funding PRESERVE and multiple aritinercept indications while still posting US$31.7 million of quarterly profit and a trailing net margin near triple digits, and has raised 2026 revenue guidance to a range of US$325 to US$330 million.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Aurinia Bear Case: Concentration Risk Still Front And Center

The cautious view hangs on Aurinia Pharmaceuticals staying too dependent on one drug while newer projects fail to pick up the slack.

"Even with encouraging Phase I tolerability and biomarker effects for aritinercept and initial studies now running across several autoimmune indications, any delay or inconclusive signal in these programs would prolong reliance on a single commercial product and may cap future revenue diversification and earnings growth."

Q3 keeps that concern alive. Revenue and net income remain tied to LUPKYNIS, with no fresh contribution from aritinercept or the Kezar portfolio. Guidance of US$325 to US$330 million for 2026 confirms current momentum and yet offers no new milestone that reduces product concentration or integration risk.

Hunt For Mispriced Earnings Stories

Aurinia Pharmaceuticals shows how strong reported profitability can still leave investors hesitant. The real opportunity could sit in stocks the market has not fully priced yet.

• Company 1 - 23% below our estimate - serves accelerating hyperscale data center investment by expanding capacity and order visibility.
• Company 2 - 20% below our estimate - grows a membership-focused teahouse network as new sites shift sales toward faster-growing regions.
• Company 3 - 21% below our estimate - adds manufacturing capacity targeting higher value AI data center optics and complex photonics programs.

Three companies from the same screener. Open the full list of 30 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com